PIK3CA and overgrowth syndrome: Originally approved for treating PIK3CA-mutated, hormone receptor-positive advanced breast cancer [9] and overgrowth syndromes [10], alpelisib has also shown efficacy in managing non-islet cell tumor hypoglycemia [11].